Medtronic InSync ICD Could Sidetep Panel Review Pending Defib Data
This article was originally published in The Gray Sheet
Medtronic's InSync ICD may not require advisory panel review if the company can produce adequate data to support the defibrillation portion of the device.
You may also be interested in...
Guidant's Contak CD "continued access policy" IDE could augment the company's pivotal trial and allow the firm to avoid returning for a second review by the Circulatory System Devices Panel.
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.